• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

UK - Articles and news items

epidermolysis-abeona

Abeona enrols 5th patient in gene therapy Epidermolysis Bullosa trial

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

EB-101 is the company’s lead gene therapy program for patients suffering with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of…

progression-ms

Novartis’ long term RRMS drug limits disease progression

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

Gilenya impacts four key measures of disease activity: relapses, MRI lesions, brain shrinkage (brain volume loss) and disability progression…

antibiotics resistance

Antibiotics: resist the resistance

Blog, Z Homepage promo / 15 September 2016 / Niamh Louise Marriott, Digital Content Producer

European Pharmaceutical Review caught up with Destiny Pharma’s CEO, Dr Love, for an exclusive interview to discuss why the pharmaceutical industry needs to radically change its approach to antibiotics in order to combat the threat of bacterial resistance…

designation-orphan-drug

Orphan drug designation granted to Boehringer Ingelheim’s systemic sclerosis drug

Industry news / 13 September 2016 / Niamh Louise Marriott, Digital Content Producer

Senscis is specifically evaluating nintedanib to understand the disease process and potential benefit of the compound to treat SSc-ILD…

insomnia-trial-completion

Ergomed and Ferrer complete recruitment for Phase IIa insomnia clinical trial

Industry news / 13 September 2016 / Niamh Louise Marriott, Digital Content Producer

The effects of lorediplon (5 and 10 mg) are being compared to both placebo and zolpidem. The aim of the study is to evaluate the appropriate effective dose of lorediplon, to further characterise its efficacy on sleep maintenance/sleep quality and to evaluate any next day hangover effects in adult patients with insomnia disorder…

coil-pill-iud

NICE says coil is more effective than pill as emergency contraception

Industry news / 8 September 2016 / Niamh Louise Marriott, Digital Content Producer

The coil is the most effective form of emergency contraception for up to 5 days after unprotected sex or within 5 days of expected ovulation…

traumatic-brain-injury

Vasopharm enrols first patient in phase III traumatic brain injury trial

Industry news / 8 September 2016 / Niamh Louise Marriott, Digital Content Producer

Vasopharm’s ronopternin (VAS203) will be evaluated for its safety and efficacy as the first patient is enrolled into the nostra phase III (NO Synthase in TRAumatic Brain Injury) trial – a clinical study to assess whether the drug can be used as a initial treatment for moderately to severely injured closed head traumatic brain (TBI) injury patients…

roche-skin-cancer-not-effective

NICE says Roche’s skin cancer drug not cost effective

Industry news / 6 September 2016 / Niamh Louise Marriott, Digital Content Producer

The committee agreed the combination offers life extending benefit compared to vemurafenib alone, however compared to alternative treatments it is too expensive. About 1,000 people would have been eligible each year…

license-asia-cancer-drug

Asian licensing deals for Ergomed and Aeterna Zentaris’ endometrial cancer drug

Industry news / 6 September 2016 / Niamh Louise Marriott, Digital Content Producer

Aeterna Zentaris signed an exclusive license agreement with affiliates of Orient EuroPharma for its lead anti-cancer compound, zoptrex, for the initial…

SA-ANTIBIOTIC-RESISTANCE

Destiny’s SA trial shows fast acting antibiotic too quick for disease resistance

Industry news / 5 September 2016 / Niamh Louise Marriott, Digital Content Producer

The two-stage clinical trial studied the safety, tolerability, and efficacy of intra-nasally applied exeporfinium chloride gels. Part 1 yielded safety data in eight volunteers and allowed progression to Part 2 in 48 healthy volunteers with colonised nasal Staphylococcus aureus (SA) bacteria. Part 2 was double-blinded, placebo controlled, and investigated two exeporfinium chloride concentration gels (0.5 & 2.0mg/g) and two viscosities (2% and 4%) applied into the nostrils for 5 days…

Featured-Image

Alzheimer’s disease: reviewing the immediate treatment horizon

Blog, Z Homepage promo / 5 September 2016 / Stuart Goodman, Blue Latitude Health

Blue Latitude Health’s Stuart Goodman discusses the latest progress in Alzheimer’s disease research and treatment to find out why a cure remains elusive…

prostate-cancer-drug-approved-nhs

NICE recommends Bayer’s prostate cancer drug for routine NHS use

Industry news / 2 September 2016 / Niamh Louise Marriott, Digital Content Producer

NICE has today issued draft final guidance recommending radium-223 dichloride (Xofigo, Bayer) as an option for treating prostate cancer…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +